on Gimv (EBR:GIMB)
Gimv Leads €51 Million Investment in Exciva for Alzheimer's Therapy
European investment company Gimv has successfully led a €51 million Series B financing round for Exciva GmbH, a biopharma firm based in Heidelberg. Co-led by EQT Life Sciences, the round also saw participation from Fountain Healthcare Partners, LifeArc, Modi VC, Carma Fund, and existing investor Andera Partners.
The funding will advance Exciva's lead compound, Deraphan, into a Phase II trial targeting agitation in Alzheimer's patients. The trial will span Europe, the United States, and Canada. Deraphan's Phase I study confirmed its safety and tolerability.
Andreas Jurgeit, Gimv Partner, highlighted the therapy's potential to improve upon existing treatment options. Philip Scheltens of EQT Life Sciences emphasized the innovation's promise in an area with limited treatment choices. The study aims to address critical unmet needs in Alzheimer's care.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Gimv news